BR0314554A - ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores - Google Patents

ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores

Info

Publication number
BR0314554A
BR0314554A BR0314554-9A BR0314554A BR0314554A BR 0314554 A BR0314554 A BR 0314554A BR 0314554 A BR0314554 A BR 0314554A BR 0314554 A BR0314554 A BR 0314554A
Authority
BR
Brazil
Prior art keywords
inflammatory
immunomodulatory agents
application
basic fatty
fatty alcohol
Prior art date
Application number
BR0314554-9A
Other languages
English (en)
Inventor
Meir Shinitzky
Irun R Cohen
Raanan Margalit
Yaacov Herzig
Jeffrey Sterling
Gyorgy Toth
Istvan Miskolczi
Ferenc Rantal
Tivadar Tamas
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR0314554A publication Critical patent/BR0314554A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"éSTERES BáSICOS DE áLCOOIS GRAXOS E SUA APLICAçãO COMO AGENTES ANTI-INFLAMATóRIOS OU IMUNOMODULADORES". A presente invenção refere-se a ésteres básicos de álcoois graxos da fórmula geral: R1 - O - CO - A ou sais farmaceuticamente aceitáveis dos mesmos, em que R1 é C~ 12~-C~ 24~ alquila ou C~ 10~-C~ 24~alquenila, e A é um resíduo contendo no mínimo um grupamento acíclico ou cíclico amino e/ou no mínimo um anel heteroaromático contendo um átomo de nitrogênio terciário ou quaternário, que são agentes anti-inflamatórios e imunomodulatórios, úteis no tratamento de inflamação mediada imunologicamente, e como adjuvantes para antígenos envolvidos tanto na resposta celular quanto na humoral.
BR0314554-9A 2002-10-10 2003-10-09 ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores BR0314554A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41715702P 2002-10-10 2002-10-10
PCT/IL2003/000820 WO2004032824A2 (en) 2002-10-10 2003-10-09 Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents

Publications (1)

Publication Number Publication Date
BR0314554A true BR0314554A (pt) 2005-08-09

Family

ID=32093977

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314554-9A BR0314554A (pt) 2002-10-10 2003-10-09 ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores

Country Status (15)

Country Link
US (1) US8987263B2 (pt)
EP (1) EP1551495A4 (pt)
JP (1) JP2006502213A (pt)
KR (1) KR20050071565A (pt)
CN (1) CN100582085C (pt)
AU (1) AU2003269466B2 (pt)
BR (1) BR0314554A (pt)
CA (1) CA2501318A1 (pt)
IS (1) IS7781A (pt)
MX (1) MXPA05003870A (pt)
NO (1) NO20052229L (pt)
NZ (1) NZ539106A (pt)
RU (1) RU2337093C2 (pt)
WO (1) WO2004032824A2 (pt)
ZA (1) ZA200502613B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
US20090118225A1 (en) * 2007-09-28 2009-05-07 Cortria Corporation 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury
US8334240B2 (en) * 2008-10-06 2012-12-18 Nalco Company Compositions and methods for inhibiting the agglomeration of hydrates in a process
US8105987B2 (en) 2008-10-06 2012-01-31 Nalco Company Corrosion inhibitors for an aqueous medium
US8105988B2 (en) 2008-10-06 2012-01-31 Nalco Company Corrosion inhibitors for a fluid
US8329620B2 (en) * 2008-10-06 2012-12-11 Nalco Company Compositions and methods for inhibiting the agglomeration of hydrates
US10392573B2 (en) 2008-10-17 2019-08-27 Ecolab Usa Inc. Method of controlling gas hydrates in fluid systems
US8921478B2 (en) 2008-10-17 2014-12-30 Nalco Company Method of controlling gas hydrates in fluid systems
US8288323B2 (en) 2009-03-02 2012-10-16 Nalco Company Compositions containing amide surfactants and methods for inhibiting the formation of hydrate agglomerates
US8618025B2 (en) 2010-12-16 2013-12-31 Nalco Company Composition and method for reducing hydrate agglomeration
US9505707B2 (en) 2010-12-22 2016-11-29 Nalco Company Composition and method for reducing hydrate agglomeration
EP2870135A1 (en) * 2012-07-05 2015-05-13 Yeda Research and Development Co. Ltd. Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors
US20140248371A1 (en) 2013-01-10 2014-09-04 Carmel-Haifa University Economic Corp. Ltd. Spalax fibroblast-derived anti-cancer agents
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) * 1909-10-07 2002-10-01 Medivir Ab Prodrugs
CH448122A (de) * 1963-10-14 1967-12-15 Hoffmann La Roche Verfahren zur Herstellung von Estern
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US3629111A (en) * 1970-10-02 1971-12-21 Olin Corp Hydraulic fluids containing novel inhibitor compositions
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
DE2234399A1 (de) * 1972-07-17 1974-01-31 Thomae Gmbh Dr K Hautschutzmittel
NO761120L (pt) * 1975-04-07 1976-10-08 Ici Ltd
FR2383662A1 (fr) * 1977-03-15 1978-10-13 Cassenne Lab Sa Nouvelles compositions a usage cosmetique
FR2420545A1 (fr) 1978-03-20 1979-10-19 Anvar Nouveaux esters de l'acide n-acetyl-muramyl-aminoacyl-glutamique ou des derives de substitution de celui-ci a proprietes anti-infectieuses et/ou d'adjuvants immunologiques
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
EP0064366A1 (en) * 1981-04-29 1982-11-10 Beecham Group Plc Pharmaceutical compositions
JPS5892607A (ja) * 1981-11-26 1983-06-02 Lion Corp 毛髪化粧料
DE3482551D1 (de) * 1983-10-26 1990-07-26 Kanebo Ltd Proteinhaltiges emulgiermittel, dessen herstellung und dieses enthaltende emulgierte kosmetische zusammensetzung.
US4749694A (en) * 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
JPS61103826A (ja) 1984-10-25 1986-05-22 Kao Corp 抗炎症剤
JPS61226977A (ja) * 1985-03-30 1986-10-08 Toshiba Corp 発光素子
JP2522682B2 (ja) * 1987-12-22 1996-08-07 コニカ株式会社 感度の高いハロゲン化銀写真感光材料
JPH01190798A (ja) * 1988-01-27 1989-07-31 Kao Corp 漂白剤組成物
JP2819415B2 (ja) * 1988-06-03 1998-10-30 富山化学工業株式会社 養毛剤
CH679119A5 (pt) * 1988-05-13 1991-12-31 Sandoz Ag
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
JP2857882B2 (ja) * 1988-11-02 1999-02-17 富山化学工業株式会社 ピロキシカムのプラスター剤
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
JP2607751B2 (ja) 1989-07-14 1997-05-07 オートイミューン インク 自己免疫性ブドウ膜網膜炎の治療予防薬
US5194451A (en) * 1989-11-02 1993-03-16 Katz David H Systemic anti-inflammatory treatment
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
JPH03170405A (ja) * 1989-11-29 1991-07-24 Nippon Oil & Fats Co Ltd 魚類の誘引剤
IL97985A0 (en) 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
MX9301789A (es) 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
JP3211987B2 (ja) * 1992-07-31 2001-09-25 ソニー株式会社 磁気記録媒体
JPH0825857B2 (ja) * 1993-04-28 1996-03-13 株式会社資生堂 アミノ酸長鎖アルキルエステル化タンパクからなる毛髪処理剤
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
JP3413303B2 (ja) * 1995-01-20 2003-06-03 花王株式会社 液体柔軟仕上剤組成物
AU5360796A (en) 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US5945401A (en) 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
TW355153B (en) * 1996-05-21 1999-04-01 Toshiba Machine Co Ltd A method for leveling abrasive cloth and device for the same
KR100528816B1 (ko) 1996-09-17 2005-11-16 아바니르 파마슈티컬스 장쇄 알코올, 알칸, 지방산 및 아미드에 의한 바이러스억제 방법
JPH10101630A (ja) * 1996-09-30 1998-04-21 Sankyo Co Ltd 新規化合物Ｂ−５３５４ａ、Ｂ−５３５４ｂ及びＢ−５３５４ｃ
KR20060061409A (ko) 1996-10-11 2006-06-07 스카리스타 리미티드 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6210700B1 (en) * 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
US6242426B1 (en) 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
EP0919230A1 (en) * 1997-12-01 1999-06-02 Societe Des Produits Nestle S.A. NMIFA's as anti-inflammatory agents in superficial mammal tissues
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
KR20010041238A (ko) 1998-02-23 2001-05-15 뉴로크린 바이오사이언시즈 인코퍼레이티드 인슐린의 펩티드 동족체를 사용하는 당뇨병의 치료 방법
JPH11343235A (ja) 1998-04-02 1999-12-14 Ajinomoto Co Inc アミノ酸誘導体および炎症因子活性化抑制剤
TW544310B (en) * 1998-04-02 2003-08-01 Ajinomoto Kk Amino acid derivatives and anti-inflammatory agents
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
DE19828352A1 (de) * 1998-06-25 1999-12-30 Clariant Gmbh Synergistische Mischungen von Phosphorsäureestern mit Carbonsäuren oder Carbonsäurederivaten als Asphalten-Dispergatoren
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6118020A (en) 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
JP2003506462A (ja) 1999-06-25 2003-02-18 ダーハム ファーマシューティカルズ リミテッド 皮膚浸透剤を含む局所処方物およびその使用
JP2002097137A (ja) * 2000-07-19 2002-04-02 Junichi Sudo パーキンソン病の予防および／または治療剤
DE10043196B4 (de) 2000-09-01 2008-10-02 W.C. Heraeus Gmbh Glaskeramikmasse und Verwendung der Glaskeramikmasse
JP4350288B2 (ja) * 2000-09-21 2009-10-21 花王株式会社 ベタインエステルの製造法
GB2372058B (en) * 2001-02-13 2004-01-28 Schlumberger Holdings Viscoelastic compositions
JP2002241317A (ja) * 2001-02-20 2002-08-28 Hirotaka Ihara 光学活性認識剤、それを用いた光学分割カラム充填剤および光学分割方法
IL142536A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
US6943197B2 (en) * 2002-06-21 2005-09-13 Howard I. Maibach Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses
KR100900448B1 (ko) * 2002-07-09 2009-06-02 엘지전자 주식회사 고밀도 광디스크의 패킷 엔코딩 타임 스탬프 기록방법
US20080221115A1 (en) 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2008106092A1 (en) 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses

Also Published As

Publication number Publication date
RU2337093C2 (ru) 2008-10-27
JP2006502213A (ja) 2006-01-19
AU2003269466A1 (en) 2004-05-04
NO20052229L (no) 2005-07-06
KR20050071565A (ko) 2005-07-07
IS7781A (is) 2005-03-31
CN100582085C (zh) 2010-01-20
US20060173053A1 (en) 2006-08-03
NO20052229D0 (no) 2005-05-09
EP1551495A4 (en) 2010-06-02
MXPA05003870A (es) 2005-06-22
EP1551495A2 (en) 2005-07-13
US8987263B2 (en) 2015-03-24
NZ539106A (en) 2007-02-23
WO2004032824A3 (en) 2004-08-26
ZA200502613B (en) 2006-10-25
RU2005114374A (ru) 2006-02-27
WO2004032824A2 (en) 2004-04-22
CA2501318A1 (en) 2004-04-22
CN1703394A (zh) 2005-11-30
AU2003269466B2 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
BR0314554A (pt) ésteres básicos de álcoois graxos e sua aplicação como agentes anti-inflamatórios ou imunomoduladores
UY27368A1 (es) Nuevos compuestos
BRPI0407262A (pt) Derivados de malonamida como inibidores gama-secretase
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BR0313154A (pt) Novos lipopeptìdeos imunogênicos que compreendem epitopos de célula t-helper e de célula b
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
BR0017028A (pt) Lipopepìdeos como agentes antibacterianos
DK1353911T3 (da) Antivirale midler
BR0017026A (pt) Lipeptìdeos como agentes antibacterianos
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
UY26957A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
ATE522507T1 (de) Montelukast in fester phase
DOP2002000544A (es) Formas de sal e-2-metoxi-n-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino] quinazolin-6-il} alil) acetamida y procedimiento de producción
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
PA8451801A1 (es) Derivados de la 9-oxima eritromicina
BR0109430A (pt) Derivados amidoxima de ácido propenocarboxìlico, processo para a preparação dos mesmos, e composições farmacêuticas que contêm os mesmos
ATE455761T1 (de) Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
BR0208999A (pt) Processo para a preparação de ácido de cefpodoxima
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
DE69828522D1 (de) Antithrombotische mittel
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.